Although p53 expression levels may be directly repressed by miRNAs (Swarbrick et al., 2010), deregulation of the ARF/MDM2 pathway appears to be the most biologically relevant and the most “druggable” target contributing to p53 functional inactivation in neuroblastoma cells. The gene discussed is MDM2; the disease is neuroblastoma.